CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Abilify® Tablets (Aripiprazole tablets), 2, 5, 10, 15, 20 and 30mg. The product is available for shipment now. Aripiprazole tablets are are indicated for the following: (A) Bipolar I disorder, (B) Irritability, associated
Read more
CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Hyzaar® Tablets (Losartan Potassium and Hydrochlorothiazide tablets), 50-12.5mg, 100-12.5mg and 100-25mg. The product is available now. Losartan Potassium-HCTZ is used to treat high blood pressure (hypertension). It is also used to lower the
Read more
CRANBURY, NJ – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Cymbalta® Capsules (Duloxetine delayed-release capsules), 20mg, 30mg and 60mg. The product is available now. Duloxetine is used to treat major depressive disorder in adults. Duloxetine is also used to treat general anxiety
Read more
CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Telmisartan tablets, 20mg, 40mg and 80mg, which are AB-rated equivalents to Micardis® by Boehringer Ingelheim. “This recent approval continues to support Solco’s ability to provide high quality, cost effective medications to those in need,” said Hai Wang, President of Solco Healthcare. Telmisartan tablets
Read more
CRANBURY, NJ — Solco Healthcare today announced the launch of generic version of Daiichi-Sankyo’s Benicar-HCT®, Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20mg/12.5mg, 40/12.5mg and 40mg/25mg. Solco received its final approval by the U.S. FDA for its abbreviated New Drug Application (ANDA) via its parent company Prinston Pharmaceutical Inc. Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for
Read more
CRANBURY, NJ — Solco Healthcare is proud to announce its FDA approval for Doxycycline Hyclate delayed-release tablets, 150mg and 200mg, which are AB-rated equivalents to Doryx® by Mayne Pharmaceutical. “This new product launch demonstrates the capabilities of the Prinston/Solco team in developing, manufacturing and bringing a difficult to formulate product to market. As one of
Read more
CRANBURY, NJ – August 11, 2016 – Solco Healthcare U.S. is proud to announce that the U.S. Food and Drug Administration (FDA) approved its generic equivalent of Vfend ® Tablets (Voriconazole Tablets), 50 mg and 200 mg. The Company is preparing for the commercialization of this product and expects to launch the product soon. “We
Read more